Protalex, Inc., a clinical-stage biopharmaceutical company, is now enrolling patients in a Phase I/II open-label, dose-escalating study of PRTX-100 in adults with persistent/chronic ITP. Pre-clinical data indicate that PRTX-100 may have the potential to treat ITP by reducing the immune-mediated destruction of the platelets.

France, United Kingdom

https://clinicaltrials.gov/ct2/show/NCT02566603?recrs=a&cond=ITP&draw=1&rank=5

Recruiting